Sales of Philadelphia-born gene therapy product hit $27M during first year
In its first year, Luxturna — the first Food and Drug Administrative-approved gene therapy treatment for an inherited disease — generated $27 million in sales for Philadelphia-based Spark Therapeutics.
Spark said it has shipped 75 vials of Luxturna, a one-time gene therapy used to treat adult and pediatric patients with v ision loss caused by inherited retinal dystrophy from a genetic mutation. The inherited retinal disorder, which leads to blindness if untreated, afflicts an estimated 1,000…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: John George Source Type: news
More News: American Health | Blindness | Gene Therapy | Genetics | Health Management | Opthalmology | Pediatrics | Reflex Sympathetic Dystrophy | Vitamin A